Wealthfront Advisers LLC Invests $43,000 in COMPASS Pathways plc (NASDAQ:CMPS)

Wealthfront Advisers LLC purchased a new position in shares of COMPASS Pathways plc (NASDAQ:CMPS) in the fourth quarter, Holdings Channel.com reports. The fund purchased 11,250 shares of the company’s stock, valued at approximately $43,000.

A number of other institutional investors also recently modified their holdings of the business. Conservest Capital Advisors Inc. raised its holdings in shares of COMPASS Pathways by 28.9% during the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock worth $51,000 after buying an additional 3,000 shares in the last quarter. SVB Wealth LLC acquired a new position in shares of COMPASS Pathways during the 4th quarter worth $101,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of COMPASS Pathways during the 4th quarter worth $41,000. Flagship Harbor Advisors LLC acquired a new position in COMPASS Pathways in the 4th quarter worth about $43,000. Finally, Hennion & Walsh Asset Management Inc. increased its holdings in COMPASS Pathways by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company’s stock worth $661,000 after purchasing an additional 26,787 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Trading Down 6.9 %

NASDAQ CMPS opened at $3.22 on Wednesday. The business’s 50-day moving average price is $3.95 and its two-hundred day moving average price is $4.92. COMPASS Pathways plc has a 12 month low of $3.17 and a 12 month high of $10.31. The firm has a market capitalization of $298.41 million, a PE ratio of -1.46 and a beta of 2.29. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). On average, analysts expect that COMPASS Pathways plc will post -2.33 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Stifel Nicolaus assumed coverage on COMPASS Pathways in a report on Thursday, February 27th. They issued a “buy” rating and a $11.00 target price for the company. Canaccord Genuity Group lowered their target price on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $18.00 target price on shares of COMPASS Pathways in a report on Wednesday, January 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of COMPASS Pathways in a report on Tuesday, March 4th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $21.83.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.